Mechanisms of resistance to EGFR targeted therapies

 Abstract

EGFR is a validated therapeutic target in many human cancers. EGFR targeted therapies are in widespread clinical use in patients with non-small cell lung cancer and other tumor types. Despite the clinical success of EGFR targeted therapy, resistance to treatment is a significant barrier to the optimized use of EGFR inhibitors to cure patients with lung and other cancers. Here, we review established and emerging mechanisms of resistance to EGFR targeted therapy and highlight strategies that could overcome treatment resistance and therefore enhance clinical outcomes.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
304 - 314
doi
10.4161/cbt.23627
Type
Review
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Mechanisms of resistance to EGFR targeted therapies